Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
brain cancer
Fierce Pharma
Servier rounds out rare cancer offerings with $2.5B Day One buy
Servier has unveiled a deal to acquire commercial-stage Day One Biopharmaceuticals and its med Ojemda for $21.50 per share in cash.
Fraiser Kansteiner
Mar 6, 2026 10:14am
Potential brain tumor pill shrinks tumors in mice
Jan 28, 2026 2:00pm
Imvax takes brain cancer therapy to FDA despite missing primary
Dec 2, 2025 8:00am
NCI axes funding for pediatric brain cancer trial consortium
Aug 26, 2025 6:50am
Alpheus nets $52M for ultrasound-activated brain tumor therapy
May 16, 2025 12:26pm
Telix shows 'promising’ 13-month OS in ph. 2 brain cancer study
Apr 16, 2025 6:30am
